Data are available from the National Cancer Institute Healthcare Delivery Research Program for researchers who meet the criteria for access to the dataset. Access to the de-identified SEER-MHOS dataset requires the approval from National Cancer Institute. The application to access the SEER-MHOS dataset can be found at <https://healthcaredelivery.cancer.gov/seer-mhos/>.

Introduction {#sec005}
============

Falls and balance/walking difficulty are significant concerns in older adults. Nearly one in four adults aged ≥65 years fall annually \[[@pone.0208573.ref001]\]. Among those who fall, 20%-30% sustain serious injuries \[[@pone.0208573.ref002]\]. While falls are multifactorial, balance and gait disorders are major risk factors \[[@pone.0208573.ref003]\]. Falls and balance/walking difficulty precipitate institutionalization, functional declines, activity restrictions, fears of falling, and recurrent falls \[[@pone.0208573.ref002],[@pone.0208573.ref004]--[@pone.0208573.ref007]\].

A cancer survivor is a person from the time of cancer diagnosis until death \[[@pone.0208573.ref008]\]. Approximately 50% of new cancers each year are diagnosed in people aged ≥65 years \[[@pone.0208573.ref009]\]. Research suggests that fall rates are higher in older cancer survivors than non-cancer individuals (33% vs. 30% in a community-dwelling sample \[[@pone.0208573.ref010]\] and 26% vs. 22% among Medicare beneficiaries \[[@pone.0208573.ref011]\]). In a study of cancer survivors in outpatient setting, balance/walking difficulty (19.4%-23.9%) was identified as the leading functional problem \[[@pone.0208573.ref012]\]. Older women post-cancer diagnosis \<5 years were more likely to report "unable to walk a half mile" than non-cancer controls (ORs = 1.34--1.92) \[[@pone.0208573.ref013]\]. In older cancer survivors, faster walking speed predicted lower mortality \[[@pone.0208573.ref014]\]. Walking likely reflects function of physiologic systems that may be affected by cancer.

In older cancer survivors, falls and balance/walking difficulty are linked to poor quality of life \[[@pone.0208573.ref015],[@pone.0208573.ref016]\]. Common risk factors for falls in older adults, including age, gender, polypharmacy, and opioid use are not predictive of falls in older cancer survivors \[[@pone.0208573.ref017],[@pone.0208573.ref018]\]. A history of falls, impaired cognition or vision, psychotropic drugs, comorbidity, and balance/walking disorders are associated with falls in cancer survivors \[[@pone.0208573.ref017],[@pone.0208573.ref019]--[@pone.0208573.ref023]\]. Balance/walking difficulty in survivors were primary examined in the context related to cancer treatment. Breast cancer survivors had reduced balance after Taxane chemotherapy \[[@pone.0208573.ref024]\]. Prostate cancer survivors receiving androgen deprivation therapy (ADT) had greater declines in balance over 3 years than survivors without ADT or non-cancer controls \[[@pone.0208573.ref025]\]. Research about factors linked to balance/walking difficulty in cancer survivors is sparse.

Sequelae associated with cancer and cancer treatments vary widely across cancer types \[[@pone.0208573.ref026]--[@pone.0208573.ref028]\]. As such, investigating factors linked to falls and balance/walking difficulty in each cancer is necessary. Using population-based data, this study aimed to identify factors linked to self-reported falls and balance/walking difficulty in the past 12 months in older survivors of breast, colorectal, lung, and prostate cancer.

Methods {#sec006}
=======

Design and data {#sec007}
---------------

This observational, cross-sectional study was approved by Institute Review Board of University of Michigan-Flint. SEER includes cancer-related information, such as cancer diagnosis, cancer stage, time of diagnosis, histology, and cancer treatment, except for chemotherapy and hormonal therapy \[[@pone.0208573.ref029]\]. MHOS collects demographics and patient-reported outcomes in health, function, symptoms, and quality of life \[[@pone.0208573.ref029],[@pone.0208573.ref030]\]. Centers for Medicare & Medicaid Services administers MHOS to randomly selected beneficiaries of Medicare Advantage Organizations each year, and participants are resurveyed 2 years later \[[@pone.0208573.ref029],[@pone.0208573.ref030]\].

Participants {#sec008}
------------

We extracted data from cohorts 9--14 (January 2006-December 2014) from SEER-MHOS linkage. Inclusion criteria were: age at cancer diagnosis ≥65 years, first primary breast, colorectal, lung, or prostate cancer, first MHOS completed from each participant during years 1--5 post-cancer diagnosis, and availability of cancer staging information. Applying these criteria resulted in 9,540 survivors (breast = 2,725, colorectal = 1,646, lung = 752, and prostate cancer = 4,245). These four cancer diagnoses were chosen because they are the most prevalent cancer types in adults aged 65 years and over \[[@pone.0208573.ref031]\]. Additionally, previous research has indicated that the prevalence of falls and balance/walking difficulty increased from pre- to post-cancer diagnosis in older breast, lung, and prostate cancer survivors \[[@pone.0208573.ref032]\]. [Fig 1](#pone.0208573.g001){ref-type="fig"} shows sample flowchart.

![Flowchart of study sample.](pone.0208573.g001){#pone.0208573.g001}

Primary outcomes {#sec009}
----------------

Falls and balance/walking difficulty were determined by two MHOS questions: (1) "A fall is when your body goes to the ground without being pushed. Did you fall in the past 12 months?" (2) "In the past 12 months, have you had a problem with balance or walking?" Responses were "no" (coded as 1) or "yes" (coded as 2).

Variables {#sec010}
---------

[Table 1](#pone.0208573.t001){ref-type="table"} provides detailed descriptions of variables. Demographics included gender, race, and marital status. Health-related variables included number of comorbidities (arthritis, osteoporosis, angina, congestive heart failure, myocardial infarction, stroke, hypertension, emphysema/asthma/chronic obstructive pulmonary disease, diabetes, low back pain, and obesity), limitation in moderate activities, number of activities of daily living (ADL) dependence, fatigue, depression, urinary incontinence, visual, hearing, or sensory impairments, and pain interfering with work. Cancer-related variables included age at cancer diagnosis, time since cancer diagnosis, cancer type, stage, surgery, and radiation. The time since cancer diagnosis was from the time of cancer diagnosis to the time when a participant completed the MHOS.

10.1371/journal.pone.0208573.t001

###### List of variables, detailed definition, and coding.

![](pone.0208573.t001){#pone.0208573.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                      Definition                                                                                                                                                                 Coding
  --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  Gender                                        Survey reported gender.                                                                                                                                                    1 = Men\
                                                                                                                                                                                                                           2 = Women

  Race                                          Race from enrollment data base maintained by Center for Medicare and Medicaid Services.                                                                                    1 = White\
                                                                                                                                                                                                                           2 = Black or other race

  Marital status                                Survey reported marital status.                                                                                                                                            1 = Married\
                                                                                                                                                                                                                           2 = Divorced, separated, widowed, or never married

  Limitation in moderate physical activity      Health limiting one in moderate activities during a typical day, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.                               1 = Not limited or limited a little\
                                                                                                                                                                                                                           2 = Yes limited a lot

  Activities of daily living (ADL) dependence   Difficulty doing six ADL without special equipment or help from another person (bathing, dressing, eating, getting in or out of chairs, walking, and using toilet).        1 = Independent (no difficulty)\
                                                                                                                                                                                                                           2 = Dependence in one or more ADL (have difficulty or unable to perform the activity)

  Fatigue                                       Fatigue during the past 4 weeks.                                                                                                                                           1 = No fatigue\
                                                                                                                                                                                                                           2 = Yes fatigue

  Urinary incontinence                          Accidentally leaked urine in the last 6 months.                                                                                                                            1 = No\
                                                                                                                                                                                                                           2 = Yes

  Vision problem                                Able to see well enough to read newspaper print (with glasses or contacts if that's how one sees best).                                                                    1 = Yes\
                                                                                                                                                                                                                           2 = No

  Hearing problem                               Able to hear most of the things people say (with a hearing aid if that's how one hears best).                                                                              1 = Yes\
                                                                                                                                                                                                                           2 = No

  Sensory impairment in feet                    Numbness or loss of feeling in feet, tingling or burning sensation in feet especially at night, decreased ability to feel hot or cold with feet during the past 4 weeks.   1 = Not impaired\
                                                                                                                                                                                                                           2 = Yes impaired

  Pain interfering with work                    Pain in the past 4 week interferes with normal work (including both work outside the home and housework)                                                                   1 = Not interfering with work\
                                                                                                                                                                                                                           2 = Yes interfering with work

  Cancer stage                                  Surveillance, Epidemiology, and End Results (SEER) summary stage 2000, derived from Collaborative Stage (CS)                                                               1 = In situ\
                                                                                                                                                                                                                           2 = Localized\
                                                                                                                                                                                                                           3 = Regional\
                                                                                                                                                                                                                           4 = Distant

  Radiation                                     Radiation therapy performed as part of the first course of cancer treatment.                                                                                               1 = No radiation\
                                                                                                                                                                                                                           2 = Yes, with radiation

  Surgery                                       Surgery of primary site that removes and/or destroys tissue of the primary site performed as part of the initial work-up or first course of therapy.                       1 = No surgery\
                                                                                                                                                                                                                           2 = Yes, with surgery
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Statistical analysis {#sec011}
--------------------

Statistical analyses were performed using IBM-SPSS 24 (IBM Corp., Armonk, NY). Analyses were conducted relating to each primary outcome separately for each cancer. Descriptive statistics were calculated for sample characteristics. Univariable logistic regression was performed to examine associations of each factor with primary outcomes. Subsequently, all demographic, health- and cancer-related variables were entered into multivariable logistic regression models to identify independent factors linked to each of the primary outcomes. Multicollinearity was determined by variance inflation factor ≥4 \[[@pone.0208573.ref033]\]. Model fit was assessed by Hosmer and Lemeshow test \[[@pone.0208573.ref034]\]. Two-sided significance level was *p*\<0.05.

Results {#sec012}
=======

Sample characteristics {#sec013}
----------------------

Average age at MHOS administration was 76.8 (6.3) years for breast, 78.5 (6.7) years for colorectal, 77.1 (5.8) years for lung, and 76.0 (5.6) years for prostate cancer. Average time post-diagnosis was 35.0 (13.7) months for breast, 35.3 (13.8) months for colorectal, 31.2 (13.5) months for lung, and 35.9 (13.8) months for prostate cancer. Percentages of survivors reporting falls in the past 12 months were 25.6% in breast, 23.3% in colorectal, 25.3% in lung, and 19.7% in prostate cancer. Balance/walking difficulty in the past 12 months was reported in 38.4% of breast, 35.3% of colorectal, 45.4% of lung, and 27.5% of prostate cancer survivors.

Univariable analyses {#sec014}
--------------------

As shown in Tables [2](#pone.0208573.t002){ref-type="table"}--[5](#pone.0208573.t005){ref-type="table"}, in breast, colorectal, and prostate cancer, being white and unmarried were associated with increased odds of falls. In colorectal cancer, women were more likely to report falls than men. In all cancer types, all health-related factors were associated with increased falls. Except for lung cancer, advancing age at cancer diagnosis was associated with increased falls. In breath cancer, local or regional cancer stage was associated with increased risk of falls, whereas radiotherapy was associated with decreased falls. On the other hand, surgery in prostate cancer were associated with decreased falls.

10.1371/journal.pone.0208573.t002

###### Crude and adjusted odds ratios for self-reported falls and balance/walking difficulty in the past 12 months by demographic, health- and cancer-related factors in breast cancer.
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  Variables                                 Falls         Balance or Walking Difficulty                                                                                                                                                                                                                                        
  ----------------------------------------- ------------- ------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- ------------- ------------- -------------------------------------------------------------------- -------------------------------------------------------------------
  Race                                                                                                                                                                                                                                                                                                                         
      White                                 1390          510                             1.0                                                               1.0                                                               1179          721           1.0                                                                  1.0
      Other                                 458           125                             **0.74 (0.60--0.93)**[^**b**^](#t002fn005){ref-type="table-fn"}   **0.65 (0.48--0.87)**[^**b**^](#t002fn005){ref-type="table-fn"}   347           229           1.08 (0.89--1.31)                                                    0.91 (0.66--1.25)
  Marital status                                                                                                                                                                                                                                                                                                               
      Married                               773           234                             1.0                                                               1.0                                                               684           318           1.0                                                                  1.0
      Not married                           1067          391                             **1.21 (1.00--1.46)**[^**a**^](#t002fn004){ref-type="table-fn"}   1.04 (0.82--1.32)                                                 833           623           **1.61 (1.36--1.90)**[^**c**^](#t002fn006){ref-type="table-fn"}      0.99 (0.76--1.56)
  Comorbidity                               2.8 (1.7)     3.6 (1.9)                       **1.26 (1.19--1.33)**[^**c**^](#t002fn006){ref-type="table-fn"}   **1.09 (1.02--1.17)**[^**a**^](#t002fn004){ref-type="table-fn"}   2.5 (1.6)     3.9 (1.8)     **1.61 (1.52--1.71)**[^**c**^](#t002fn006){ref-type="table-fn"}      **1.19 (1.09--1.29)**[^**c**^](#t002fn006){ref-type="table-fn"}
  Moderate physical activity                                                                                                                                                                                                                                                                                                   
      Not limited                           1463          383                             1.0                                                               1.0                                                               1329          514           1.0                                                                  1.0
      Limited a lot                         352           245                             **2.66 (2.09--3.47)**[^**c**^](#t002fn006){ref-type="table-fn"}   1.11 (0.82--1.51)                                                 169           425           **6.50 (5.30--7.98)**[^**c**^](#t002fn006){ref-type="table-fn"}      1.10 (0.78--1.56)
  ADL dependency                                                                                                                                                                                                                                                                                                               
      None                                  1179          234                             1.0                                                               1.0                                                               1200          214           1.0                                                                  1.0
      1--2 ADL                              431           180                             **2.10 (1.68--2.63)**[^**c**^](#t002fn006){ref-type="table-fn"}   1.34 (0.98--1.81)                                                 235           372           **8.88 (7.13--11.04)**[^**c**^](#t002fn006){ref-type="table-fn"}     **4.92 (3.62-.6.69)**[^**c**^](#t002fn006){ref-type="table-fn"}
      3+ ADL                                170           193                             **5.72 (4.46--7.34)**[^**c**^](#t002fn006){ref-type="table-fn"}   **1.97 (1.32--2.93)**[^**b**^](#t002fn005){ref-type="table-fn"}   46            316           **38.52 (27.37--54.22)**[^**c**^](#t002fn006){ref-type="table-fn"}   **12.55 (7.65--20.60)**[^**c**^](#t002fn006){ref-type="table-fn"}
  Fatigue                                                                                                                                                                                                                                                                                                                      
      No                                    1449          368                             1.0                                                               1.0                                                               1307          504           1.0                                                                  1.0
      Yes                                   361           251                             **2.74 (2.25--3.34)**[^**c**^](#t002fn006){ref-type="table-fn"}   1.11 (0.83--1.49)                                                 186           425           **5.93 (4.85--7.24)**[^**c**^](#t002fn006){ref-type="table-fn"}      **1.69 (1.22--2.34)**[^**b**^](#t002fn005){ref-type="table-fn"}
  Depression                                                                                                                                                                                                                                                                                                                   
      No                                    1248          283                             1.0                                                               1.0                                                               1104          427           1.0                                                                  1.0
      Yes                                   398           280                             **3.10 (2.54--3.80)**[^**c**^](#t002fn006){ref-type="table-fn"}   **2.07 (1.61--2.66)**[^**c**^](#t002fn006){ref-type="table-fn"}   256           418           **4.22 (3.49--5.11)**[^**c**^](#t002fn006){ref-type="table-fn"}      **2.20 (1.65--2.93)**[^**c**^](#t002fn006){ref-type="table-fn"}
  Urinary incontinence                                                                                                                                                                                                                                                                                                         
      No                                    1029          228                             1.0                                                               1.0                                                               908           345           1.0                                                                  1.0
      Yes                                   796           399                             **2.26 (1.88--2.73)**[^**c**^](#t002fn006){ref-type="table-fn"}   **1.63 (1.29--2.05)**[^**c**^](#t002fn006){ref-type="table-fn"}   599           593           **2.61 (2.20--3.08)**[^**c**^](#t002fn006){ref-type="table-fn"}      **1.64 (1.26--2.13)**[^**c**^](#t002fn006){ref-type="table-fn"}
  Vision problem                                                                                                                                                                                                                                                                                                               
      No                                    1746          556                             1.0                                                               1.0                                                               1463          831           1.0                                                                  1.0
      Yes                                   90            67                              **2.34 (1.68--3.25)**[^**c**^](#t002fn006){ref-type="table-fn"}   1.03 (0.78--1.36)                                                 48            108           **3.96 (2.79--5.62)**[^**c**^](#t002fn006){ref-type="table-fn"}      **1.98 (1.09--3.57)**[^**a**^](#t002fn004){ref-type="table-fn"}
  Hearing problem                                                                                                                                                                                                                                                                                                              
      No                                    1599          503                             1.0                                                               1.0                                                               1343          750           1.0                                                                  1.0
      Yes                                   185           114                             **1.96 (1.52--2.53)**[^**c**^](#t002fn006){ref-type="table-fn"}   1.09 (0.77--1.53)                                                 130           169           **2.33 (1.82--2.98)**[^**c**^](#t002fn006){ref-type="table-fn"}      1.05 (0.70--1.58)
  Sensory impairment                                                                                                                                                                                                                                                                                                           
      No                                    1457          429                             1.0                                                               1.0                                                               1283          598           1.0                                                                  1.0
      Yes                                   202           138                             **2.32 (1.82--2.96)**[^**c**^](#t002fn006){ref-type="table-fn"}   1.15 (0.84--1.57)                                                 90            248           **5.91 (4.56--7.67)**[^**c**^](#t002fn006){ref-type="table-fn"}      **1.86 (1.09--1.29)**[^**b**^](#t002fn005){ref-type="table-fn"}
  Pain interfering with work                                                                                                                                                                                                                                                                                                   
      No                                    1091          242                             1.0                                                               1.0                                                               1052          284           1.0                                                                  1.0
      Moderate or Severe                    732           386                             **2.38 (1.97--2.86)**[^**c**^](#t002fn006){ref-type="table-fn"}   1.03 (0.78--1.36)                                                 455           653           **5.32 (4.45--6.35)**[^**c**^](#t002fn006){ref-type="table-fn"}      1.08 (0.80--1.45)
  Age at diagnosis, y                       72.8 (5.9)    74.7 (6.8)                      **1.05 (1.03--1.06)**[^**c**^](#t002fn006){ref-type="table-fn"}   **1.03 (1.01--1.05)**[^**b**^](#t002fn005){ref-type="table-fn"}   72.5 (5.7)    74.7 (6.7)    **1.06 (1.05--1.08)**[^**c**^](#t002fn006){ref-type="table-fn"}      **1.02 (1.00--1.05)**[^**a**^](#t002fn004){ref-type="table-fn"}
  Survival time since cancer diagnosis, m   34.7 (13.7)   35.8 (14.0)                     1.01 (0.99--1.01)                                                 1.01 (1.00--1.02)                                                 34.8 (13.8)   35.6 (13.6)   1.00 (1.00--1.01)                                                    1.00 (0.99--1.01)
  Cancer stage                                                                                                                                                                                                                                                                                                                 
      In situ                               342           85                              1.0                                                               1.0                                                               280           144           1.0                                                                  1.0
      Localized                             1096          399                             **1.47 (1.13--1.91)**[^**b**^](#t002fn005){ref-type="table-fn"}   **1.88 (1.29--2.70)**[^**b**^](#t002fn005){ref-type="table-fn"}   928           563           1.18 (0.94--1.48)                                                    1.42 (0.99--2.04)
      Regional                              381           144                             **1.52 (1.12--2.06)**[^**b**^](#t002fn005){ref-type="table-fn"}   **1.74 (1.14--2.64)**[^**a**^](#t002fn004){ref-type="table-fn"}   300           224           **1.45 (1.11--1.89)**[^**b**^](#t002fn005){ref-type="table-fn"}      **1.58 (1.04--2.40)**[^**a**^](#t002fn004){ref-type="table-fn"}
      Distant                               33            9                               1.10 (0.51--2.38)                                                 1.15 (0.39--3.34)                                                 21            22            **2.04 (1.08--3.83)**[^**a**^](#t002fn004){ref-type="table-fn"}      1.20 (0.42--3.44)
  Surgery                                                                                                                                                                                                                                                                                                                      
      No                                    44            21                              1.0                                                               1.0                                                               28            38            1.0                                                                  1.0
      Yes                                   1804          616                             0.72 (0.42--1.21)                                                 0.89 (0.39--2.06)                                                 1498          914           **0.45 (0.27--0.74)**[^**b**^](#t002fn005){ref-type="table-fn"}      0.55 (0.21--1.43)
  Radiation                                                                                                                                                                                                                                                                                                                    
      No                                    820           344                             1.0                                                               1.0                                                               640           520           1.0                                                                  1.0
      Yes                                   994           287                             **0.69 (0.57--0.83)**[^**c**^](#t002fn006){ref-type="table-fn"}   **0.75 (0.59--0.96)**[^**a**^](#t002fn004){ref-type="table-fn"}   855           423           **0.61 (0.52--0.72)**[^**c**^](#t002fn006){ref-type="table-fn"}      0.80 (0.61--1.04)

Abbreviation: ADL, activities of daily living.

Values show are number, mean (SD), or ORs (95%CI).

Statistically significant ORs are marked in bold text with numerical superscripts indicating the level of significance.

^a^ *p*-value \<0.05,

^b^ *p*-value \<0.05, and

^c^ *p*-value \<0.05.

10.1371/journal.pone.0208573.t003

###### Crude and adjusted odds ratios for self-reported falls and balance/walking difficulty in the past 12 months by demographic, health- and cancer-related factors in colorectal cancer.

![](pone.0208573.t003){#pone.0208573.t003g}

  Variables                                 Falls         Balance or Walking Difficulty                                                                                                                                                                                                                                        
  ----------------------------------------- ------------- ------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- ------------- ------------- -------------------------------------------------------------------- ------------------------------------------------------------------
  Gender                                                                                                                                                                                                                                                                                                                       
      Men                                   576           148                             1.0                                                               1.0                                                               495           224           1.0                                                                  1.0
      Women                                 604           204                             **1.31 (1.03--1.67)**[^**a**^](#t003fn004){ref-type="table-fn"}   1.23 (0.88--1.73)                                                 490           313           **1.41 (1.14--1.75)**[^**b**^](#t003fn005){ref-type="table-fn"}      1.09 (0.77--1.56)
  Race                                                                                                                                                                                                                                                                                                                         
      White                                 576           148                             1.0                                                               1.0                                                               753           435           1.0                                                                  1.0
      Other                                 604           204                             **0.73 (0.54--0.99)**[^**a**^](#t003fn004){ref-type="table-fn"}   0.69 (0.46--1.02)                                                 233           106           0.79 (0.61--1.02)                                                    **0.57 (0.38--0.87)**[^**b**^](#t003fn005){ref-type="table-fn"}
  Marital status                                                                                                                                                                                                                                                                                                               
      Married                               612           159                             1.0                                                               1.0                                                               535           227           1.0                                                                  1.0
      Not married                           557           193                             **1.33 (1.05--1.69)**[^**a**^](#t003fn004){ref-type="table-fn"}   0.98 (0.70--1.38)                                                 443           306           **1.63 (1.32--2.01)**[^**c**^](#t003fn006){ref-type="table-fn"}      1.13 (0.79--1.62)
  Comorbidity                               2.5 (1.8)     3.4 (2.0)                       **1.25 (1.17--1.34)**[^**c**^](#t003fn006){ref-type="table-fn"}   **1.13 (1.03--1.23)**[^**b**^](#t003fn005){ref-type="table-fn"}   2.2 (1.6)     3.7 (1.9)     **1.54 (1.43--1.66)**[^**c**^](#t003fn006){ref-type="table-fn"}      **1.23 (1.12--1.36)**[^**c**^](#t003fn006){ref-type="table-fn"}
  Moderate physical activity                                                                                                                                                                                                                                                                                                   
      Not limited                           926           208                             1.0                                                               1.0                                                               850           273           1.0                                                                  1.0
      Limited a lot                         245           148                             **2.67 (1.87--3.80)**[^**c**^](#t003fn006){ref-type="table-fn"}   0.92 (0.61--1.38)                                                 130           265           **6.35 (4.94--8.15)**[^**c**^](#t003fn006){ref-type="table-fn"}      **1.58 (1.05--2.38)**[^**a**^](#t003fn004){ref-type="table-fn"}
  ADL dependency                                                                                                                                                                                                                                                                                                               
      None                                  791           128                             1.0                                                               1.0                                                               787           130           1.0                                                                  1.0
      1--2 ADL                              246           104                             **2.61 (1.94--3.51)**[^**c**^](#t003fn006){ref-type="table-fn"}   **1.86 (1.26--2.76)**[^**b**^](#t003fn005){ref-type="table-fn"}   145           201           **8.39 (6.32--11.14)**[^**c**^](#t003fn006){ref-type="table-fn"}     **4.63 (3.18--6.76)**[^**c**^](#t003fn006){ref-type="table-fn"}
      3+ ADL                                120           106                             **5.46 (3.96--7.53)**[^**c**^](#t003fn006){ref-type="table-fn"}   **3.37 (2.02--5.62)**[^**c**^](#t003fn006){ref-type="table-fn"}   43            182           **25.62 (17.51--37.49)**[^**c**^](#t003fn006){ref-type="table-fn"}   **6.39 (3.73--10.92)**[^**c**^](#t003fn006){ref-type="table-fn"}
  Fatigue                                                                                                                                                                                                                                                                                                                      
      No                                    916           199                             1.0                                                               1.0                                                               833           272           1.0                                                                  1.0
      Yes                                   245           153                             **2.88 (2.23--3.70)**[^**c**^](#t003fn006){ref-type="table-fn"}   1.35 (0.92--1.98)                                                 141           257           **5.58 (4.36--7.15)**[^**c**^](#t003fn006){ref-type="table-fn"}      1.34 (0.90--1.99)
  Depression                                                                                                                                                                                                                                                                                                                   
      No                                    810           192                             1.0                                                               1.0                                                               732           261           1.0                                                                  1.0
      Yes                                   264           138                             **2.97 (2.46--3.60**)[^**c**^](#t003fn006){ref-type="table-fn"}   **1.63 (1.16--2.28)**[^**b**^](#t003fn005){ref-type="table-fn"}   180           220           **3.43 (2.69--4.37)**[^**c**^](#t003fn006){ref-type="table-fn"}      **1.52 (1.06--2.19)**[^**a**^](#t003fn004){ref-type="table-fn"}
  Urinary incontinence                                                                                                                                                                                                                                                                                                         
      No                                    761           178                             1.0                                                               1.0                                                               687           247           1.0                                                                  1.0
      Yes                                   397           174                             **1.87 (1.47--2.39)**[^**c**^](#t003fn006){ref-type="table-fn"}   1.06 (0.77--1.46)                                                 290           275           **2.64 (2.12--3.29)**[^**c**^](#t003fn006){ref-type="table-fn"}      1.10 (0.79--1.54)
  Vision problem                                                                                                                                                                                                                                                                                                               
      No                                    1082          312                             1.0                                                               1.0                                                               926           458           1.0                                                                  1.0
      Yes                                   89            45                              **1.75 (1.20--2.56)**[^**b**^](#t003fn005){ref-type="table-fn"}   0.99 (0.59--1.65)                                                 59            76            **2.60 (1.82--3.73)**[^**c**^](#t003fn006){ref-type="table-fn"}      1.55 (0.88--2.71)
  Hearing problem                                                                                                                                                                                                                                                                                                              
      No                                    961           275                             1.0                                                               1.0                                                               839           385           1.0                                                                  1.0
      Yes                                   174           81                              **1.63 (1.21--2.19)**[^**b**^](#t003fn005){ref-type="table-fn"}   0.86 (0.57--1.30)                                                 125           131           **2.28 (1.74--3.00)**[^**c**^](#t003fn006){ref-type="table-fn"}      0.96 (0.62--1.48)
  Sensory impairment                                                                                                                                                                                                                                                                                                           
      No                                    941           232                             1.0                                                               1.0                                                               827           341           1.0                                                                  1.0
      Yes                                   146           101                             **2.81 (2.10--3.76)**[^**c**^](#t003fn006){ref-type="table-fn"}   **1.73 (1.18--2.52)**[^**b**^](#t003fn005){ref-type="table-fn"}   87            155           **4.32 (3.23--5.78)**[^**c**^](#t003fn006){ref-type="table-fn"}      **2.64 (1.73--4.04)**[^**c**^](#t003fn006){ref-type="table-fn"}
  Pain interfering with work                                                                                                                                                                                                                                                                                                   
      No                                    752           156                             1.0                                                               1.0                                                               723           178           1.0                                                                  1.0
      Moderate or Severe                    425           198                             **2.25 (1.76--2.86)**[^**c**^](#t003fn006){ref-type="table-fn"}   0.89 (0.61--1.30)                                                 264           356           **5.48 (4.36--6.88)**[^**c**^](#t003fn006){ref-type="table-fn"}      1.39 (0.79--1.54)
  Age at diagnosis, y                       74.4 (6.6)    76.8 (6.9)                      **1.05 (1.04--1.07)**[^**c**^](#t003fn006){ref-type="table-fn"}   **1.04 (1.01--1.06)**[^**b**^](#t003fn005){ref-type="table-fn"}   73.9 (6.4)    77.1 (6.8)    **1.08 (1.06--1.09)**[^**c**^](#t003fn006){ref-type="table-fn"}      **1.04 (1.02--1.07)**[^**b**^](#t003fn005){ref-type="table-fn"}
  Survival time since cancer diagnosis, m   35.2 (13.6)   35.4 (14.2)                     1.00 (0.99--1.01)                                                 1.00 (0.99--1.01)                                                 35.0 (13.8)   35.5 (13.8)   1.00 (1.00--1.01)                                                    1.01 (0.99--1.02)
  Cancer stage                                                                                                                                                                                                                                                                                                                 
      In situ                               79            26                              1.0                                                               1.0                                                               71            43            1.0                                                                  1.0
      Localized                             649           172                             0.87 (0.55--1.37)                                                 0.76 (0.41--1.38)                                                 566           292           0.85 (0.57--1.28)                                                    1.08 (0.55--2.12)
      Regional                              448           160                             1.15 (0.72--1.84)                                                 1.18 (0.64--2.20)                                                 380           220           0.96 (0.63--1.45)                                                    1.36 (0.68--2.71)
      Distant                               54            10                              0.60 (0.27--1.33)                                                 0.39 (0.14--1.11)                                                 39            25            1.06 (0.56--1.99)                                                    1.24 (0.44--3.44)
  Surgery                                                                                                                                                                                                                                                                                                                      
      No                                    27            11                              1.0                                                               1.0                                                               24            13            1.0                                                                  1.0
      Yes                                   1160          349                             0.74 (0.36--1.50)                                                 1.06 (0.47--3.05)                                                 969           531           1.01 (0.51--2.00)                                                    1.57 (0.49--5.03)
  Radiation                                                                                                                                                                                                                                                                                                                    
      No                                    1067          323                             1.0                                                               1.0                                                               891           493           1.0                                                                  1.0
      Yes                                   114           34                              0.99 (0.66--1.47)                                                 1.08 (0.65--1.82)                                                 100           44            0.80 (0.55--1.15)                                                    0.70 (0.40--1.23)

Abbreviation: ADL, activities of daily living.

Values show are number, mean (SD), or ORs (95%CI).

Statistically significant ORs are marked in bold text with numerical superscripts indicating the level of significance.

^a^ *p*-value \<0.05,

^b^ *p*-value \<0.05, and

^c^ *p*-value \<0.05.

10.1371/journal.pone.0208573.t004

###### Crude and adjusted odds ratios for self-reported falls and balance/walking difficulty in the past 12 months by demographic, health- and cancer-related factors in lung cancer.

![](pone.0208573.t004){#pone.0208573.t004g}

  Variables                                 Falls                                     Balance or Walking Difficulty                                                                                                                                                                                                                                                                                                          
  ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------- ----------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------
  Gender                                                                                                                                                                                                                                                                                                                                                                                                                     
      Men                                   255                                       77                                        1.0                                                               1.0                                                               185                                       146                                       1.0                                                                  1.0
      Women                                 254                                       98                                        1.28 (0.91--1.81)                                                 1.22 (0.74--2.03)                                                 188                                       165                                       1.11 (0.82--1.50)                                                    0.69 (0.42--1.14)
  Race                                                                                                                                                                                                                                                                                                                                                                                                                       
      White                                 411                                       146                                       1.0                                                               1.0                                                               306                                       251                                       1.0                                                                  1.0
      Other                                 106                                       29                                        0.77 (0.49--1.21)                                                 0.81 (0.43--1.53)                                                 71                                        63                                        1.08 (0.74--1.58)                                                    1.27 (0.70--2.31)
  Marital status                                                                                                                                                                                                                                                                                                                                                                                                             
      Married                               294                                       95                                        1.0                                                               1.0                                                               213                                       174                                       1.0                                                                  1.0
      Not married                           214                                       79                                        1.14 (0.81--1.62)                                                 0.73 (0.45--1.21)                                                 159                                       135                                       1.04 (0.77--1.41)                                                    1.05 (0.64--1.72)
  Comorbidity                               3.2 (1.9)                                 3.7 (2.0)                                 **1.14 (1.03--1.26)**[^**c**^](#t004fn006){ref-type="table-fn"}   0.91 (0.79--1.04)                                                 2.9 (1.8)                                 3.9 (1.9)                                 **1.34 (1.22--1.47)**                                                1.07 (0.93--1.23)
  Moderate physical activity                                                                                                                                                                                                                                                                                                                                                                                                 
      Not limited                           330                                       71                                        1.0                                                               1.0                                                               270                                       129                                       1.0                                                                  1.0
      Limited a lot                         176                                       101                                       **2.67 (1.88--3.80)**[^**c**^](#t004fn006){ref-type="table-fn"}   1.04 (0.60--1.82)                                                 99                                        179                                       **3.78 (2.74--5.23)**[^**c**^](#t004fn006){ref-type="table-fn"}      1.12 (0.66--1.92)
  ADL dependency                                                                                                                                                                                                                                                                                                                                                                                                             
      None                                  282                                       40                                        1.0                                                               1.0                                                               258                                       63                                        1.0                                                                  1.0
      1--2 ADL                              141                                       55                                        **2.75 (1.75--4.33)**[^**c**^](#t004fn006){ref-type="table-fn"}   1.70 (0.94--3.07)                                                 82                                        115                                       **5.74 (3.87--8.53)**[^**c**^](#t004fn006){ref-type="table-fn"}      **3.39 (2.00--5.72)**[^**c**^](#t004fn006){ref-type="table-fn"}
      3+ ADL                                84                                        72                                        **6.04 (3.83--9.54)**[^**c**^](#t004fn006){ref-type="table-fn"}   **4.13 (2.02--8.42)**[^**c**^](#t004fn006){ref-type="table-fn"}   31                                        124                                       **16.38 (10.13--26.48)**[^**c**^](#t004fn006){ref-type="table-fn"}   **7.14 (3.44--14.80)**[^**c**^](#t004fn006){ref-type="table-fn"}
  Fatigue                                                                                                                                                                                                                                                                                                                                                                                                                    
      No                                    305                                       74                                        1.0                                                               1.0                                                               254                                       125                                       1.0                                                                  1.0
      Yes                                   198                                       96                                        **2.00 (1.41--2.84**)[^**c**^](#t004fn006){ref-type="table-fn"}   1.17 (0.68--1.99)                                                 113                                       181                                       **3.26 (2.37--4.47)**[^**c**^](#t004fn006){ref-type="table-fn"}      1.36 (0.81--2.28)
  Depression                                                                                                                                                                                                                                                                                                                                                                                                                 
      No                                    313                                       69                                        1.0                                                               1.0                                                               254                                       129                                       1.0                                                                  1.0
      Yes                                   157                                       87                                        **2.24 (1.74--2.88)**[^**c**^](#t004fn006){ref-type="table-fn"}   **1.87 (1.12--3.10)**[^**a**^](#t004fn004){ref-type="table-fn"}   93                                        149                                       **3.16 (2.26--4.41)**[^**c**^](#t004fn006){ref-type="table-fn"}      **1.70 (1.03--2.81)**[^**a**^](#t004fn004){ref-type="table-fn"}
  Urinary incontinence                                                                                                                                                                                                                                                                                                                                                                                                       
      No                                    348                                       81                                        1.0                                                               1.0                                                               265                                       163                                       1.0                                                                  1.0
      Yes                                   163                                       89                                        **2.35 (1.65--3.34)**[^**c**^](#t004fn006){ref-type="table-fn"}   **1.85 (1.16--2.96)**[^**a**^](#t004fn004){ref-type="table-fn"}   107                                       144                                       **2.19 (1.59--3.01)**[^**c**^](#t004fn006){ref-type="table-fn"}      1.23 (0.77--1.98)
  Vision problem                                                                                                                                                                                                                                                                                                                                                                                                             
      No                                    471                                       146                                       1.0                                                               1.0                                                               351                                       266                                       1.0                                                                  1.0
      Yes                                   42                                        26                                        **2.00 (1.18--3.37)**[^**a**^](#t004fn004){ref-type="table-fn"}   1.06 (0.49--2.27)                                                 23                                        45                                        **2.58 (1.52--4.37)**[^**c**^](#t004fn006){ref-type="table-fn"}      1.55 (0.67--3.56)
  Hearing problem                                                                                                                                                                                                                                                                                                                                                                                                            
      No                                    426                                       134                                       1.0                                                               1.0                                                               320                                       241                                       1.0                                                                  1.0
      Yes                                   72                                        38                                        **1.68 (1.08--2.60)**[^**a**^](#t004fn004){ref-type="table-fn"}   0.83 (0.45--1.53)                                                 46                                        63                                        **1.82 (1.20--2.76)**[^**b**^](#t004fn005){ref-type="table-fn"}      0.91 (0.50--1.67)
  Sensory impairment                                                                                                                                                                                                                                                                                                                                                                                                         
      No                                    391                                       104                                       1.0                                                               1.0                                                               313                                       182                                       1.0                                                                  1.0
      Yes                                   81                                        50                                        **2.32 (1.54--3.51)**[^**c**^](#t004fn006){ref-type="table-fn"}   **1.74 (1.02--2.98)**[^**a**^](#t004fn004){ref-type="table-fn"}   37                                        94                                        **4.37 (2.87--6.66)**[^**c**^](#t004fn006){ref-type="table-fn"}      **2.84 (1.56--5.17)**[^**b**^](#t004fn005){ref-type="table-fn"}
  Pain interfering with work                                                                                                                                                                                                                                                                                                                                                                                                 
      No                                    256                                       52                                        1.0                                                               1.0                                                               222                                       83                                        1.0                                                                  1.0
      Moderate or Severe                    255                                       117                                       **2.26 (1.56--3.27)**[^**c**^](#t004fn006){ref-type="table-fn"}   1.34 (0.78--2.31)                                                 148                                       226                                       **4.08 (2.95--5.66)**[^**c**^](#t004fn006){ref-type="table-fn"}      1.57 (0.98--2.52)
  Age at diagnosis, y                       73.7 (5.6)                                74.4 (6.0)                                1.02 (0.99--1.05)                                                 **1.05 (1.01--1.09)**[^**a**^](#t004fn004){ref-type="table-fn"}   73.2 (5.4)                                74.8 (6.1)                                **1.05 (1.02--1.07)**[^**c**^](#t004fn006){ref-type="table-fn"}      **1.06 (1.01--1.11)**[^**b**^](#t004fn005){ref-type="table-fn"}
  Survival time since cancer diagnosis, m   31.4 (13.5)                               31.7 (13.7)                               1.00 (0.99--1.01)                                                 1.01 (0.99--1.02)                                                 31.4 (13.4)                               31.5 (13.7)                               1.00 (0.99--1.01)                                                    1.01 (0.99--1.03)
  Cancer stage                                                                                                                                                                                                                                                                                                                                                                                                               
      In situ                               0[^d^](#t004fn007){ref-type="table-fn"}   0[^d^](#t004fn007){ref-type="table-fn"}                                                                                                                                       0[^d^](#t004fn007){ref-type="table-fn"}   0[^d^](#t004fn007){ref-type="table-fn"}                                                                        
      Localized                             261                                       84                                        1.0                                                               1.0                                                               197                                       147                                       1.0                                                                  1.0
      Regional                              209                                       68                                        1.01 (0.70--1.46)                                                 0.65 (0.38--1.11)                                                 159                                       119                                       1.00 (0.73--1.38)                                                    0.76 (0.45--1.28)
      Distant                               98                                        32                                        1.02 (0.64--1.62)                                                 1.24 (0.61--2.53)                                                 65                                        64                                        1.32 (0.88--1.98)                                                    1.19 (0.58--2.46)
  Surgery                                                                                                                                                                                                                                                                                                                                                                                                                    
      No                                    203                                       80                                        1.0                                                               1.0                                                               137                                       146                                       1.0                                                                  1.0
      Yes                                   313                                       95                                        0.77 (0.55--1.09)                                                 1.34 (0.70--2.56)                                                 239                                       168                                       **0.66 (0.49--0.90)**[^**b**^](#t004fn005){ref-type="table-fn"}      0.95 (0.50--1.79)
  Radiation                                                                                                                                                                                                                                                                                                                                                                                                                  
      No                                    363                                       121                                       1.0                                                               1.0                                                               268                                       215                                       1.0                                                                  1.0
      Yes                                   149                                       53                                        1.07 (0.73--1.55)                                                 1.52 (0.81--2.86)                                                 106                                       96                                        1.13 (0.81--1.57)                                                    0.87 (0.47--1.64)

Abbreviation: ADL, activities of daily living.

Values show are number, mean (SD), or ORs (95%CI).

Statistically significant ORs are marked in bold text with numerical superscripts indicating the level of significance.

^a^ *p*-value \<0.05,

^b^ *p*-value \<0.05, and

^c^ *p*-value \<0.05.

^d^ There were no survivors with the stage "in situ".

10.1371/journal.pone.0208573.t005

###### Crude and adjusted odds ratios for self-reported falls and balance/walking difficulty in the past 12 months by demographic, health- and cancer-related factors in prostate cancer.

![](pone.0208573.t005){#pone.0208573.t005g}

  Variables                                 Falls                                     Balance or Walking Difficulty                                                                                                                                                                                                                                                                                                           
  ----------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------- ----------------------------------------- ----------------------------------------- -------------------------------------------------------------------- -----------------------------------------------------------------
  Race                                                                                                                                                                                                                                                                                                                                                                                                                        
      White                                 2305                                      604                                       1.0                                                                1.0                                                               2102                                      796                                       1.0                                                                  1.0
      Other                                 707                                       135                                       **0.73 (0.59--0.89)**[^**b**^](#t005fn005){ref-type="table-fn"}    **0.67 (0.51-.0.87)**[^**b**^](#t005fn005){ref-type="table-fn"}   613                                       229                                       0.99 (0.83--1.17)                                                    0.86 (0.67--1.11)
  Marital status                                                                                                                                                                                                                                                                                                                                                                                                              
      Married                               2677                                      489                                       1.0                                                                10                                                                2064                                      695                                       1.0                                                                  1.0
      Not married                           375                                       256                                       **1.54 (1.30--1.83)**[^**c**^](#t005fn006){ref-type="table-fn"}    **1.29 (1.04--1.60)**[^**a**^](#t005fn004){ref-type="table-fn"}   676                                       341                                       **1.50 (1.28--1.75)**[^**c**^](#t005fn006){ref-type="table-fn"}      1.09 (0.87--1.36)
  Comorbidity                               2.3 (1.7)                                 3.3 (2.0)                                 **1.33 (1.27--1.40)**[^**c**^](#t005fn006){ref-type="table-fn"}    **1.11 (1.05--1.18)**[^**b**^](#t005fn005){ref-type="table-fn"}   2.1 (1.6)                                 3.5 (1.9)                                 **1.53 (1.46--1.60)**[^**c**^](#t005fn006){ref-type="table-fn"}      **1.14 (1.07--1.21)**[^**c**^](#t005fn006){ref-type="table-fn"}
  Moderate physical activity                                                                                                                                                                                                                                                                                                                                                                                                  
      Not limited                           1463                                      383                                       1.0                                                                1.0                                                               2515                                      646                                       1.0                                                                  1.0
      Limited a lot                         352                                       245                                       **3.74 (3.10--4.50)**[^**c**^](#t005fn006){ref-type="table-fn"}    **1.41 (1.07--1.86)**[^**a**^](#t005fn004){ref-type="table-fn"}   235                                       389                                       **6.44 (5.36--7.74)**[^**c**^](#t005fn006){ref-type="table-fn"}      **1.46 (1.10--1.94)**[^**b**^](#t005fn005){ref-type="table-fn"}
  ADL dependency                                                                                                                                                                                                                                                                                                                                                                                                              
      None                                  2255                                      286                                       1.0                                                                1.0                                                               2242                                      297                                       1.0                                                                  1.0
      1--2 ADL                              526                                       204                                       **3.06 (2.50--3.75)**[^**c**^](#t005fn006){ref-type="table-fn"}    **1.95 (1.49--2.54)**[^**c**^](#t005fn006){ref-type="table-fn"}   361                                       364                                       **7.61 (6.30--9.20)**[^**c**^](#t005fn006){ref-type="table-fn"}      **3.32 (2.60--4.24)**[^**c**^](#t005fn006){ref-type="table-fn"}
      3+ ADL                                230                                       243                                       **8.33 (6.70--10.36)**[^**c**^](#t005fn006){ref-type="table-fn"}   **3.73 (2.69--5.19)**[^**c**^](#t005fn006){ref-type="table-fn"}   115                                       355                                       **23.30 (18.28--29.70)**[^**c**^](#t005fn006){ref-type="table-fn"}   **6.12 (4.40--8.51)**[^**c**^](#t005fn006){ref-type="table-fn"}
  Fatigue                                                                                                                                                                                                                                                                                                                                                                                                                     
      No                                    2533                                      465                                       1.0                                                                1.0                                                               2411                                      583                                       1.0                                                                  1.0
      Yes                                   503                                       281                                       **3.04 (2.44--3.63)**[^**c**^](#t005fn006){ref-type="table-fn"}    1.09 (0.83--1.42)                                                 323                                       453                                       **5.80 (4.90--6.87)**[^**c**^](#t005fn006){ref-type="table-fn"}      **1.48 (1.14--1.92)**[^**b**^](#t005fn005){ref-type="table-fn"}
  Depression                                                                                                                                                                                                                                                                                                                                                                                                                  
      No                                    2305                                      426                                       1.0                                                                1.0                                                               2158                                      569                                       1.0                                                                  1.0
      Yes                                   554                                       264                                       **2.51 (1.75--3.59)**[^**c**^](#t005fn006){ref-type="table-fn"}    **1.28 (1.01--1.62)**[^**a**^](#t005fn004){ref-type="table-fn"}   424                                       390                                       **3.49 (2.96--4.12)**[^**c**^](#t005fn006){ref-type="table-fn"}      1.21 (0.95--1.54)
  Urinary incontinence                                                                                                                                                                                                                                                                                                                                                                                                        
      No                                    1822                                      304                                       1.0                                                                1.0                                                               1699                                      425                                       1.0                                                                  1.0
      Yes                                   1228                                      442                                       **2.16 (1.83--2.54)**[^**c**^](#t005fn006){ref-type="table-fn"}    **1.54 (1.25--1.88)**[^**c**^](#t005fn006){ref-type="table-fn"}   1045                                      615                                       **2.35 (2.03--2.72)**[^**c**^](#t005fn006){ref-type="table-fn"}      **1.64 (1.34--2.01)**[^**c**^](#t005fn006){ref-type="table-fn"}
  Vision problem                                                                                                                                                                                                                                                                                                                                                                                                              
      No                                    2895                                      668                                       1.0                                                                1.0                                                               2644                                      908                                       1.0                                                                  1.0
      Yes                                   174                                       81                                        **2.02 (1.53--2.66)**[^**c**^](#t005fn006){ref-type="table-fn"}    0.91 (0.61--1.34)                                                 117                                       136                                       **3.39 (2.61--4.38)**[^**c**^](#t005fn006){ref-type="table-fn"}      **1.74 (1.17--2.59)**[^**b**^](#t005fn005){ref-type="table-fn"}
  Hearing problem                                                                                                                                                                                                                                                                                                                                                                                                             
      No                                    2524                                      563                                       1.0                                                                1.0                                                               2327                                      750                                       1.0                                                                  1.0
      Yes                                   478                                       177                                       **1.66 (1.37--2.02)**[^**c**^](#t005fn006){ref-type="table-fn"}    1.03 (0.79--1.33)                                                 375                                       279                                       **2.31 (31.94--2.75)**[^**c**^](#t005fn006){ref-type="table-fn"}     1.07 (0.82--1.39)
  Sensory impairment                                                                                                                                                                                                                                                                                                                                                                                                          
      No                                    2566                                      532                                       1.0                                                                1.0                                                               2401                                      690                                       1.0                                                                  1.0
      Yes                                   295                                       156                                       **2.55 (2.06--3.16)**[^**c**^](#t005fn006){ref-type="table-fn"}    1.26 (0.95--1.66)                                                 186                                       263                                       **4.92 (4.00--6.05)**[^**c**^](#t005fn006){ref-type="table-fn"}      **1.84 (1.39--2.45)**[^**c**^](#t005fn006){ref-type="table-fn"}
  Pain interfering with work                                                                                                                                                                                                                                                                                                                                                                                                  
      No                                    2089                                      310                                       1.0                                                                1.0                                                               2055                                      341                                       1.0                                                                  1.0
      Moderate or Severe                    970                                       432                                       **3.00 (2.55--3.54)**[^**c**^](#t005fn006){ref-type="table-fn"}    1.07 (0.84--1.38)                                                 698                                       697                                       **6.02 (5.15--7.03)**[^**c**^](#t005fn006){ref-type="table-fn"}      **1.80 (1.43--2.28)**[^**c**^](#t005fn006){ref-type="table-fn"}
  Age at diagnosis, y                       72.1 (5.2)                                74.1 (6.3)                                **1.06 (1.05--1.08)**[^**c**^](#t005fn006){ref-type="table-fn"}    **1.04 (1.02--1.06)**[^**c**^](#t005fn006){ref-type="table-fn"}   71.8 (5.1)                                74.1 (6.2)                                **1.08 (1.06--1.09)**[^**c**^](#t005fn006){ref-type="table-fn"}      **1.05 (1.04--1.07)**[^**c**^](#t005fn006){ref-type="table-fn"}
  Survival time since cancer diagnosis, m   35.8 (13.8)                               36.1 (13.7)                               1.00 (1.00--1.01)                                                  1.00 (0.99--1.01)                                                 35.8 (13.8)                               36.0 (13.8)                               **2.35 (1.98--2.78)**[^**c**^](#t005fn006){ref-type="table-fn"}      1.00 (0.94--1.01)
  Cancer stage                                                                                                                                                                                                                                                                                                                                                                                                                
      In situ                               0[^d^](#t005fn007){ref-type="table-fn"}   0[^d^](#t005fn007){ref-type="table-fn"}                                                                                                                                        0[^d^](#t005fn007){ref-type="table-fn"}   0[^d^](#t005fn007){ref-type="table-fn"}                                                                        
      Localized                             3048                                      736                                       1.0                                                                1.0                                                               2750                                      1023                                      1.0                                                                  1.0
      Regional                              326                                       53                                        0.81 (0.55--1.19)                                                  0.81 (0.55--1.19)                                                 290                                       89                                        0.83 (0.64--1.06)                                                    1.15 (0.79--1.67)
      Distant                               55                                        26                                        1.36 (0.74--2.48)                                                  1.36 (0.74--2.48)                                                 45                                        36                                        **2.15 (1.38--3.35)**[^**b**^](#t005fn005){ref-type="table-fn"}      0.85 (.0.44--1.63)
  Surgery                                   2164                                      570                                                                                                                                                                                                                                                                                                                                     
      No                                    900                                       182                                       1.0                                                                1.0                                                               1917                                      806                                       1.0                                                                  1.0
      Yes                                                                                                                       **0.77 (0.64--0.92)**[^**b**^](#t005fn005){ref-type="table-fn"}    1.11 (0.84--1.47)                                                 846                                       236                                       **0.66 (0.56--0.78)**[^**c**^](#t005fn006){ref-type="table-fn"}      0.89 (0.67--1.18)
  Radiation                                 1637                                      423                                                                                                                                                                                                                                                                                                                                     
      No                                    1402                                      325                                       1.0                                                                1.0                                                               1452                                      599                                       1.0                                                                  1.0
      Yes                                   2164                                      570                                       0.90 (0.76--1.05)                                                  1.19 (0.93--1.50)                                                 1286                                      438                                       **0.83 (0.72--0.95)**[^**b**^](#t005fn005){ref-type="table-fn"}      0.93 (0.73--1.18)

Abbreviation: ADL, activities of daily living.

Values show are number, mean (SD), or ORs (95%CI).

Statistically significant ORs are marked in bold text with numerical superscripts indicating the level of significance.

^a^ *p*-value \<0.05,

^b^ *p*-value \<0.05, and

^c^ *p*-value \<0.05.

^d^ There were no survivors with the stage "in situ".

Tables [2](#pone.0208573.t002){ref-type="table"}--[5](#pone.0208573.t005){ref-type="table"} also present the results from univariable analyses of factors linked to balance or walking difficulty. In colorectal cancer, women were more likely to report balance/walking difficulty than men. Being unmarried was associated with balance/walking difficulty in breast, colorectal, and prostate cancer. All health-related factors and advancing age at cancer diagnosis were associated with balance/walking difficulty in all cancer types. Regional or distance cancer stage in breast cancer and distance cancer stage in prostate cancer were associated with difficulty in balance/walking. In both breast and prostate cancer, treatment with surgery and radiation was associated with reduced odds of balance/walking difficulty. Surgery also was associated with reduced balance/walking difficulty in lung cancer.

Multivariable analyses {#sec015}
----------------------

Multivariable regression revealed that ADL dependence and advancing age at cancer diagnosis were independent factors for falls and balance/walking difficulty in all cancer types (Tables [2](#pone.0208573.t002){ref-type="table"}--[5](#pone.0208573.t005){ref-type="table"}). Comorbidity was another significant independent factor linked to falls and balance/walking difficulty in breast, colorectal, and prostate cancer. Additionally, in all cancer types, depression was independently associated with falls, whereas sensory impairment was independently associated with balance/walking difficulty. Urinary incontinence was significantly associated with falls in breast, lung, and prostate cancer. In breast cancer, localized or regional cancer stage was an independent factor for increased falls and regional cancer stage was linked to balance/walking difficulty. Radiation was associated with reduced falls in breast cancer.

Discussion {#sec016}
==========

The impact of falls and balance/walking difficulty on health outcomes may be under-recognized in older cancer survivors. Only 10% of survivors with a recent fall had their falls documented by oncology clinicians \[[@pone.0208573.ref035]\]. Balance/walking difficulty is rarely recorded in outpatient oncology settings \[[@pone.0208573.ref012]\]. Current findings bring important insight about factors related to falls and balance/walking difficulty within each of four major cancers in older survivors based on population-based data. This study suggests significant factors that may be integrated into clinical screening algorithms to identify older breast, colorectal, lung, and prostate cancer survivors at risk of falling or developing balance and walking difficulty. In order to optimize function and reduce long-term disability, fall prevention in cancer survivors has been recommended as the top priorities by key stakeholders, including National Cancer Institute, National Center for Medical Rehabilitation Research, and American Congress of Rehabilitation Medicine \[[@pone.0208573.ref036],[@pone.0208573.ref037]\]. Screening is an essential first step in preventing falls and improving balance or walking ability after cancer diagnosis.

We found that among older survivors who were one to five years after the diagnosis of breast, colorectal, lung, or prostate cancer, 20%-26% reported falls and 28%-45% reported having balance/walking difficulty in the past 12 months. Analyses of Medicare/Medicaid beneficiaries showed that 26%-33% of older cancer survivors had falls \[[@pone.0208573.ref010],[@pone.0208573.ref011]\]. Methods for measuring falls in previous studies were unclear \[[@pone.0208573.ref010],[@pone.0208573.ref011]\]. MHOS collects information of falls by asking about the occurrence of falls in the past 12 months \[[@pone.0208573.ref029]\]. Recall bias and underreporting of falls \[[@pone.0208573.ref038]\] likely contributed to lower fall rates in MOHS data. Previous research reported that 46% of Medicare beneficiaries had mild-severe limitation in walking as determined by four questions about difficulty, assistive devices, and need for assistance during walking \[[@pone.0208573.ref039]\]. This study determined balance/walking difficulty based on one MHOS question, which may not reflect the full spectrum of balance skills and walking ability.

In this study, univariable analyses showed that a majority of factors associated with falls and balance/walking difficulty are similar across four cancer types. However, after multivariable analyses, independent factors of falls and balance/walking difficulty that are unique to each cancer type emerged. Additionally, within each cancer types, not all independent factors of falls were linked to balance/walking difficulty and vice versus. Cancer sequelae are specific to each cancer type \[[@pone.0208573.ref040]\] and therefore, likely have different impacts on body functions that are important in preventing falls and controlling balance and walking. Falls and balance/walking difficulty may have some common determinants, but each has a different construct. The control of balance skills and walking requires postural alignment, muscle strength, perceived stability limit, sensory integration, anticipatory and reactive postural reactions, and cognition \[[@pone.0208573.ref041]\]. While impairment in balance and walking is a major risk factor of fall, the causes of falls is multifactorial and involve other factors, such as prior falls, age, race, gender, medications, use of assistive devices, comorbidities, depression, and environmental hazards \[[@pone.0208573.ref003],[@pone.0208573.ref017]\]. Research of the general geriatric population has demonstrated that the relationship between falls and walking ability as measured by gait speed is not linear \[[@pone.0208573.ref042]\]. Older adults with higher and slower gait speed were more likely to fall than those with normal gait speed \[[@pone.0208573.ref042]\]. Taken together, risk factor profiles of falls and balance/walking difficulty in older survivors likely differ within each cancer type. Falls and balance/walking difficulty may need to be examined as major health outcomes separately.

White race was independently associated with falls in breast and prostate cancer. Race was not an independent factor of balance/walking difficulty in any cancer type. Previous research of older cancer survivors did not find fall rates to differ between white race vs. others \[[@pone.0208573.ref019],[@pone.0208573.ref043]\]. In cancer survivors treated with chemotherapy, white race was associated with increased risk of injurious falls \[[@pone.0208573.ref044]\]. A U.S. population-based study revealed that the percentages of older adults with falls in the past 3 months were 27.8% in American Indian, 17.4% in Hispanic, 13% in black/Asian/pacific islanders, and 15.8% in white \[[@pone.0208573.ref045]\]. This low fall rate in whites in the general geriatric population was in contrast to current findings of an increased odd of falls in white survivors. In early stage breast cancer, racial disparities in treatments have been reported, with black less likely to received standard care than white \[[@pone.0208573.ref046]\]. Recent population-based research with a larger sample size reported that in late stage breast cancer, racial difference in cancer treatment was not observed \[[@pone.0208573.ref047]\]. Additionally, non-significant borderline associations indicated that white women were more likely to receive chemotherapy and had worse mortality rate in comparison with black women \[[@pone.0208573.ref047]\]. Whether the interplay between race and cancer treatment affects the outcomes of falls and balance/walking difficulty was not examined in this study, and warrant further research.

In prostate cancer only, married prostate cancer survivors were less likely to report falls than those who were unmarried. Marital status, however, was not linked to balance/walking difficulty. In older men with prostate cancer, marriage was found to protect against inflammation \[[@pone.0208573.ref048]\] and promote behaviors in seeking healthcare \[[@pone.0208573.ref049]\]. In comparison with those who were not married, married prostate cancer survivors might have received more care and support to reduce fall risk, such as using assistive device, checking footwear, and modifying home environment for safety. Supportive care to reduce fall risk may be pertinent in older, unmarried prostate cancer survivors.

In older adults, female gender is a significant predictor of falls \[[@pone.0208573.ref003]\], while risk factors for falls differ between genders \[[@pone.0208573.ref050]\]. Among older cancer survivors treated with neurotoxic chemotherapy, women were more likely to fall than men \[[@pone.0208573.ref044]\]. We did not find gender to be independently associated with falls or balance/walking difficulty in colorectal or lung cancer.

Similar to prior studies \[[@pone.0208573.ref010],[@pone.0208573.ref019],[@pone.0208573.ref022],[@pone.0208573.ref044],[@pone.0208573.ref051],[@pone.0208573.ref052]\], we found significant associations of health-related factors with falls and balance/walking difficulty. ADL dependence was the only independently factor linked to both falls and balance/walking difficulty in breast, colorectal, lung, and prostate cancer. In all four cancer types, depression was an independent factor of falls whereas sensory impairment was an independent factor of balance/walking difficulty. Other health-related factors linked to falls or balance/walking difficulty differed across cancer types. Current findings underscore the need to manage impairments, functional deficits, and burden from comorbidity that may be associated with falling in older cancer survivors. Research suggested integrating comprehensive geriatric assessment (CGA) into oncology practice to guide cancer treatments and survivorship care \[[@pone.0208573.ref053]--[@pone.0208573.ref055]\]. CGA identifies comorbidity and functional impairments that may increase fall risk and warrant referrals for rehabilitation \[[@pone.0208573.ref019],[@pone.0208573.ref056]\].

Except for lung cancer, comorbidity was an independent factor of both falls and balance/walking difficulty in other cancer types. Lung cancer survivors are more likely to be diagnosed at advanced stages and receive aggressive cancer treatments resulting in a multitude of side effects \[[@pone.0208573.ref040]\]. It is possible that disease burden and symptoms from lung cancer itself has a larger impact on overall body function than other comorbidity. Findings from current and prior studies of cancer survivors showed that with each additional comorbidity, the odds of reporting falls increased by 10%-20% \[[@pone.0208573.ref019]\]. In the general geriatric population, comorbidity is also an important risk factor of falls \[[@pone.0208573.ref003]\] and walking difficulty \[[@pone.0208573.ref039]\]. Impairment from some chronic conditions, such as arthritis and stroke, increases fall risk \[[@pone.0208573.ref019],[@pone.0208573.ref057]\]. This study only examined the total number rather than the type of chronic conditions with relaiton to fall or balance/walking difficulty. Previous research of the SEER-MHOS data reported that after a cancer diagnosis, older cancer survivors developed different types of chronic conditions depending on the cancer type \[[@pone.0208573.ref058]\]. For example, in prostate cancer, musculoskeletal, major depression, gastrointestinal and pulmonary coditions were the most prevalent conditions. In breast cancer, the prevalence of diabetes and high blood pressure were the highest \[[@pone.0208573.ref058]\]. Future research is necessary to elucidate the impact of newly developed chronic conditions after a cancer diagnosis on falls and balance/walking difficulty within each cancer type.

We found that ADL dependence was independently linked to falls and balance/walking difficulty in all cancer types. Compared to those without ADL dependence, survivors with ADL dependence had two- to four-fold increase in fall risk. Additionally, ADL dependence increased the risk for balance/walking difficulty by three to thirteen times. In older adults, both improvement and deterioration in ADL over 6 years had been linked to falls \[[@pone.0208573.ref059]\]. In older cancer survivors of mixed cancer types, balance/walking difficulty was significantly associated with distress in managing household activities \[[@pone.0208573.ref016]\]. Individuals with improved ADL may be exposed to higher fall risk due to better mobility and function \[[@pone.0208573.ref059]\]. Incorporate ADL training into fall-prevention and balance/walking intervention programs may need to be considered in older cancer survivors.

Depression was independently associated with falls in all cancer types, and with balance/walking difficulty in breast, colorectal, and lung cancer. Depression is associated with decreased physical activity, sleep disorder, cognitive impairment, and use of antidepressant, which collectively increase fall risk in older adults \[[@pone.0208573.ref060]\]. Individuals with depression had impaired balance response, which may be related to deficits in integration of visual and proprioceptive inputs to control posture \[[@pone.0208573.ref061],[@pone.0208573.ref062]\]. Previous research of older survivors of mixed cancer types reported that depression increased the odds of falling \[[@pone.0208573.ref063]\]. However, in older cancer survivors who were receiving chemotherapy, depression was not associated with falls \[[@pone.0208573.ref056]\]. Because the SEER-MHOS linkage does not include chemotherapy data, this study could not determine whether the impact of depression varies by cancer treatment. No other study has examined the relationship between depression and balance/walking difficulty in older cancer survivors. Urinary incontinence was independently associated with falls in breast, lung, and prostate cancer. In breast and prostate cancer, urinary incontinence was also an independent factor of balance/walking difficulty. Previous research identified urinary incontinence as a risk factor for falls in older survivors with mixed cancer diagnoses \[[@pone.0208573.ref051]\] or advanced cancer \[[@pone.0208573.ref023]\]. Urinary incontinence is a complication of prostate cancer treatment \[[@pone.0208573.ref064]\]. Prevalence of urinary incontinence is higher in breast and prostate cancer survivors compared to non-cancer controls \[[@pone.0208573.ref065]\] Urinary incontinence is recognized as a geriatric syndrome that often co-exists with other chronic conditions \[[@pone.0208573.ref066]\].

In all cancer types, sensory impairment was an independent factors of balance/walking difficulty. In colorectal and lung cancer only, sensory impaired was independently linked to falls. We defined sensory impairment as numbness, tingling, burning, loss of decreased ability to feel in the feet in the previous 4 months. Sensory impairment is a common complication of neurotoxic chemotherapy and contributes to balance and walking problems \[[@pone.0208573.ref067]\]. In breast cancer survivors, poor performance in balance and walking was attributed to impaired ability to integrate sensory information from visual, vestibular, and somatosensory systems \[[@pone.0208573.ref024]\]. SEER-MHOS does not provide the information about chemotherapy. As such, whether sensory impairment observed in this study was related to chemotherapy or other conditions, such as peripheral neuropathy from diabetes \[[@pone.0208573.ref068],[@pone.0208573.ref069]\], cannot be acertained.

The extent of pain interfering with work was not associated with falls in all cancer types. A study of older cancer survivors showed that pain measured by Visual Analog Scale was linked to falls \[[@pone.0208573.ref052]\]. Cancer-related pain is an important factor associated with falls in survivors with advanced cancer \[[@pone.0208573.ref023]\]. We determined pain based on one MHOS question asking how often in the past 4 weeks, pain interfered with normal work. The question did not identify the location or nature of the pain. A comprehensive questionnaire specific to cancer, such as Edmonton Classification System for Cancer Pain, may elucidate the relationship between pain and falls in cancer survivors \[[@pone.0208573.ref023]\]. This study found that pain was an independent factor of balance/walking difficulty in prostate cancer only. In localized prostate cancer survivors, 69.6% reported pain in the past 3 months \[[@pone.0208573.ref070]\]. Additionally, 72.5% of pain was located at back, lower abdomen, lower extremity, or hip.^69^ Older prostate cancer survivors may encounter more difficulty in balance and walking because pain is prevalent and primarily involves the lower body in this population.

In this study, age at cancer diagnosis was the only cancer-related independent factor associated with falls and balance/walking difficulty in all cancer types. Age is a risk factor for falling in older adults \[[@pone.0208573.ref003]\]. We found that the odds for reporting falls and balance/walking difficulty increased by 3%-11% and by 2%-6%, respectively, with each additional year of age at cancer diagnosis. In survivors with advanced cancer or chemotherapy induced peripheral neuropathy, age did not predict falls \[[@pone.0208573.ref023],[@pone.0208573.ref067]\]. Age, specifically chronological age as measured in this study, is unlikely the key driver of falls and balance/walking difficulty in older cancer survivors. Research of SEER-MHOS linkage reported that older cancer survivors had greater declines in physical function over time than age-matched controls \[[@pone.0208573.ref071]\]. Cancer treatment has long-lasting impact on non-tumor cells. Vulnerabilities of genome instability, epigenetic changes, and cellular senescence likely interact with age, leading to accelerated aging observed in cancer survivors \[[@pone.0208573.ref072]\].

In breast cancer only, localized or regional cancer stage was independently associated with increased odds of falls and balance/walking difficulty. Previous research reported no associations between falls with cancer stage, cancer type, or time post-cancer diagnosis in older survivors of mixed cancer types \[[@pone.0208573.ref010]\], and in postmenopausal breast cancer survivors \[[@pone.0208573.ref073]\]. Treatments for advanced breast cancer, particularly neurotoxic chemotherapy, cause a wide variety of side effects affecting body systems. Medications prescribed to manage symptoms in advanced cancer, such as anticonvulsants, antidepressants, and antipsychotics \[[@pone.0208573.ref023],[@pone.0208573.ref074]\], are known to increase fall risk and affect physical function in older adults \[[@pone.0208573.ref075]\]. Cancer symptoms and treatment complications specific to each cancer types likely influence the associations of cancer stage with falls and balance/walking.

In breast cancer only, radiation was independently associated with reduced odds of falls, but not balance/walking difficulty. Radiotherapy is the local treatment of choice in breast cancer. Radiotherapy improved long-term outcomes and survival by reducing breast cancer recurrence and mortality \[[@pone.0208573.ref076],[@pone.0208573.ref077]\]. This study confirmed additional benefit of radiation by reducing fall risk in breast cancer. Reasons for omitting radiotherapy, such as cultural beliefs, limited access to healthcare, previous breast irradiation, inability to lie flat or abduct the arm, or having collagen vascular disease \[[@pone.0208573.ref078],[@pone.0208573.ref079]\] were not available from SEER-MHOS linkage \[[@pone.0208573.ref029]\].

This study has limitations. First, because of cross-sectional design, associations between factors with falls and balance/walking difficulty cannot be construed as causal relationships. Second, SEER-MHOS does not include information about chemotherapy or hormonal therapy \[[@pone.0208573.ref029]\]. Third, the time when a condition or impairment developed cannot be identified from SEER-MHOS data. Fourth, primary outcomes were obtained by self-report and subject to recall bias \[[@pone.0208573.ref038]\]. Lastly, MHOS randomly surveyed Medicare Advantage beneficiaries, which have more risk factors and lower function than other Medicare beneficiaries \[[@pone.0208573.ref080]\].

Conclusion {#sec017}
==========

Each of the four cancer types being examined in this study has unique patterns of demographics, health- and cancer-related factors that are independently linked to falls and balance/walking difficulty. In breast, colorectal, lung and prostate cancer, ADL dependence and age at cancer diagnosis were common independent factors linked to both falls and balance/walking difficulty. In all four cancer types, depression was an independent factor of falls whereas sensory impairment in feet was an independent factor of balance/walking difficulty. These findings have important implications in screening for older cancer survivors at risk of falls and balance/walking difficulty.
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